Refractory anemia with excess of blasts 2
ICD-10 D46.22 is a billable code used to indicate a diagnosis of refractory anemia with excess of blasts 2.
Refractory anemia with excess of blasts 2 (RAEB-2) is a subtype of myelodysplastic syndromes (MDS) characterized by ineffective hematopoiesis and the presence of a significant number of myeloblasts in the bone marrow. Specifically, RAEB-2 is defined by the presence of 10-19% myeloblasts in the bone marrow, indicating a higher risk of progression to acute myeloid leukemia (AML). Patients typically present with symptoms of anemia, such as fatigue, pallor, and weakness, alongside potential thrombocytopenia and neutropenia. The condition is often diagnosed through a combination of peripheral blood smears, bone marrow biopsies, and cytogenetic studies. Given its classification as a neoplasm of uncertain behavior, RAEB-2 requires careful monitoring and management due to its potential for progression to more aggressive forms of leukemia. Treatment options may include supportive care, growth factors, and in some cases, hematopoietic stem cell transplantation. The prognosis varies significantly based on individual patient factors, including age, overall health, and specific cytogenetic abnormalities.
Detailed lab results, including CBC and bone marrow biopsy findings.
Diagnosis and management of patients with MDS, monitoring for progression to AML.
Ensure accurate representation of blast percentages and cytogenetic abnormalities.
Comprehensive treatment plans, including chemotherapy regimens and response assessments.
Treatment of patients with RAEB-2 and evaluation for stem cell transplant eligibility.
Document any complications or secondary malignancies that may arise.
Used to monitor blood counts in patients with RAEB-2.
Document the reason for the CBC and any abnormal findings.
Hematologists should ensure that CBC results are correlated with clinical findings.
The percentage of blasts is crucial for diagnosis and prognosis; RAEB-2 is defined by 10-19% blasts, indicating a higher risk of progression to acute myeloid leukemia.
